drugset / Trial / NCT03077620

Sleep Quality and Amyloid-Beta Kinetics

NCT03077620

RandomizedParallel-groupSingle-blindOther

Summary

The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.

Timeline

Start
2016-11
Primary completion
2021-03-28
Completion
2021-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Suvorexant Small molecule 10 mg
Subject Suvorexant Small molecule 20 mg

Indications

No indication recorded.